# TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Canonical URL: https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-host-conference-call-on-first-quarter-2026-financial-results-and-business-update
Ticker: TGTX
Company: TG Therapeutics
Source: TG Therapeutics
Published: 2026-04-30 11:30 EST
Original Source URL: https://ir.tgtherapeutics.com
## Summary

Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide

## Article Body
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide
## Recent Company News
- 2026-06-03 11:30 EST — [TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-results-from-phase-1-trial-evaluating-subcutaneous-briumvir-ublituximab-xiiy) — Source: TG Therapeutics
- 2026-06-02 11:30 EST — [TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-healthcare-conference) — Source: TG Therapeutics
- 2026-06-01 11:30 EST — [TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-publication-of-post-hoc-data-from-the-phase-3-ultimate-i-and-ii-trials-in-treatment-naive-patients-with-relapsing-forms-of-ms-published-in-frontiers-in-immunology) — Source: TG Therapeutics
- 2026-05-28 11:30 EST — [TG Therapeutics to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference) — Source: TG Therapeutics
- 2026-05-27 11:30 EST — [TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-results-from-phase-3-enhance-trial) — Source: TG Therapeutics
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)